Showing results (2251-2260 of 4,522) with videos related to
Sort By:
Pageof 453
Advances in Therapy|June 8, 2022
Real-World Patient Characteristics, Treatment Patterns, and Mutation Testing Patterns Among US Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR MutationsJinghua He, Christopher D Pericone, Julie VanderpoelAdvances in Therapy|June 21, 2022
Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United StatesBijal D Shah, Nathaniel J Smith, Chaoling Feng, et al.Advances in Therapy|June 23, 2022
Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018Yifei Liu, Martha Skup, Min Yang, et al.Advances in Therapy|July 7, 2022
Preference for Type 2 Diabetes Therapies in the United States: A Discrete Choice ExperimentJay H Shubrook, Michael Radin, Sarah N Ali, et al.Advances in Therapy|July 12, 2022
Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label ExtensionRogério Souza, Marion Delcroix, Nazzareno Galié, et al.Advances in Therapy|April 11, 2022
Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect ComparisonRaul Cordoba, Thibaud Prawitz, Tracy Westley, et al.Advances in Therapy|April 11, 2022
Efficacy of IDegLira Versus IDegAsp Therapy in Patients with Type 2 Diabetes: A Randomized Crossover Study by isCGMYuji Kawaguchi, Shoko Miyamoto, Yuriko Hajika, et al.Advances in Therapy|April 11, 2022
Treatment Goals for Psoriasis as Measured by Patient Benefit Index: Results of a National Psoriasis Foundation SurveyApril Armstrong, Emily Edson-Heredia, Baojin Zhu, et al.Advances in Therapy|April 13, 2022
Cost-Effectiveness of Treating Patients with Chronic Kidney Disease and Prior Hyperkalemia with Renin-Angiotensin-Aldosterone System Inhibitor and Patiromer: A Swiss Public Healthcare PerspectiveBarbara Fischer, Andreas Serra, Harry TelserAdvances in Therapy|April 12, 2022
Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized TrialJustus G Garweg, Jana Štefanickova, Carel Hoyng, et al.Pageof 453